Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed Incorporated granted inducement awards to 13 new employees, in accordance with NASDAQ Listing Rule 5635(c)(4). The employees received options to purchase an aggregate of 93,370 shares of Insmed common stock at an exercise price of $22.64 per share. The options have a 10-year term and a four-year vesting schedule.
- None.
In connection with the commencement of their employment, the employees received options on September 1, 2023 to purchase an aggregate 93,370 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301921293.html
SOURCE Insmed Incorporated